Medicon Village
Lund 223 81
Sweden
46 4 62 75 62 20
https://abliva.com
Settore/i:
Settore:
Impiegati a tempo pieno: 8
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Ellen K. Donnelly Ph.D. | Chief Executive Officer | 4,97M | N/D | 1974 |
Ms. Catharina Jz Johansson | Deputy CEO, CFO & VP of Investor Relations | N/D | N/D | 1967 |
Dr. Eskil Elmér M.D., Ph.D. | Chief Scientific Officer & VP of Discovery | 247k | N/D | 1970 |
Daniel Schale | Director of Communications | N/D | N/D | N/D |
Dr. Magnus Hansson | Chief Medical Officer and VP of Preclinical & Clinical Development | N/D | N/D | 1976 |
Dr. Lars Vedin | Consultant | N/D | N/D | N/D |
Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
L'ISS Governance QualityScore di Abliva AB (publ) al 29 aprile 2024 è 8. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 4; diritti degli azionisti: 1; retribuzione: 10.